98%
921
2 minutes
20
Raspberry production and consumption have increased in recent years due to its polyphenol content such as anthocyanins and ketones, bioactive compounds that have been studied to reduce blood glucose levels and stabilize the blood lipid profile. The objective of this study was to systematically recover and review scientific evidence regarding the consumption of raspberry or its bioactive compounds and the action mechanisms involved in the hypoglycemic and lipid-lowering effects they present. Original articles from and enzyme inhibition studies, animal models, and human clinical studies were compiled in PubMed, Web of Science, and Science Direct databases. Studies showed satisfactory results regarding blood glucose level reduction after consumption of frozen or lyophilized raspberry, infusion of raspberry leaves, seed oil, as well as compounds, extracted from the fruit by inhibiting enzymes such as -glucosidase and dipeptidyl peptidase-4 (DPP-4) and other mechanisms that increase insulin production and insulin sensitivity. However, regarding the lipid-lowering effect, the results were heterogeneous, mainly in terms of stabilization in triglyceride levels. However, a reduction in cholesterol and low-density lipoprotein levels is reported, as well as an increase in high-density lipoproteins. According to the results, raspberry can be included in the nonpharmacological treatment of hyperglycemia and dyslipidemias; however, further research is considered necessary.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/jmf.2021.0046 | DOI Listing |
Rev Med Liege
September 2025
Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.
Type 1 diabetes (T1D) is an autoimmune chronic disease that leads to the destruction of pancreatic beta cells and thus requires lifelong insulin therapy. Constraints and adverse events associated to insulin therapy are well known as well as the risk of long-term complications linked to chronic hyperglycaemia. Symptomatic T1D is preceded by a preclinical asymptomatic period, which is characterized by the presence of at least two auto-antibodies against beta cell without disturbances of blood glucose control (stage 1) or, in addition to immunological biomarkers, by the presence of mild dysglycaemia reflecting a defect of early insulin secretion (stage 2).
View Article and Find Full Text PDFEndocrinol Diabetes Metab
September 2025
Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Liver transplantation is associated with various metabolic disorders. Peri-transplant hyperglycemia is among the most frequent metabolic disorders among liver transplant recipients. Hyperglycemia following liver transplantation can increase the risk of post-transplant complications, potentially impacting both graft and recipient outcomes.
View Article and Find Full Text PDFMethods Cell Biol
September 2025
Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France; Metabolomics and Cell Biology Platforms, UMS AMICCa, Gustave Roussy, Villejuif, France. Electronic ad
Cushing's syndrome is caused by chronic exposure to excessive levels of glucocorticoids. It is characterized by significant phenotypic alterations including increased visceral adiposity and fat deposits on the cheeks, leading to a characteristic 'moon face' appearance. Although glucocorticoid therapy is widespread, its associated side effects are of significant clinical concern.
View Article and Find Full Text PDFTher Drug Monit
September 2025
Departments of Pharmacology, and.
Background: Fluconazole-tacrolimus interactions occur, but the additional effect of ritonavir is emphasized here, underscoring the need for careful prescription reconciliation in renal transplant recipients living with HIV-AIDS to prevent accidental ritonavir coadministration and inadvertent tacrolimus toxicity. The findings provide valuable insight for therapeutic drug monitoring (TDM) specialists. Patient informed consent was obtained for publication of the anonymized data.
View Article and Find Full Text PDFOphthalmic Plast Reconstr Surg
September 2025
Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, U.S.A.
Purpose: To evaluate the efficacy and safety of teprotumumab for the treatment of thyroid eye disease in geriatric patients.
Methods: This was a multicenter cohort study of patients aged 75 and older, treated between February 2020 and September 2023 across 10 tertiary institutions. Patients were included if they had moderate-to-severe thyroid eye disease and at least 1 infusion of teprotumumab.